Historique
Rapport
4-Methylamphetamine (4-MA). Report on the risk assessment of 4-methylamphetamine in the framework of the Council Decision on new psychoactive substances
Auteur(s) :
OEDT = EMCDDA (Observatoire européen des drogues et des dépendances = European monitoring centre for drugs and drug addiction)
Année
2014
Page(s) :
59 p.
Langue(s) :
Anglais
Collection :
Risk assessments, 10
ISBN :
978-92-9168-601-8
Refs biblio. :
38
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Organismes
OEDT
Thésaurus mots-clés
DROGUES DE SYNTHESE
;
AMPHETAMINE
;
PHENOMENE EMERGENT
;
FACTEUR DE RISQUE
;
SAISIE
;
PHARMACOLOGIE
;
TYPE D'USAGE
Thésaurus géographique
EUROPE
Note de contenu :
TABLE OF CONTENTS:
Foreword
Introduction
EMCDDA actions on monitoring and responding to new drugs
EMCDDA-Europol Joint Report on 4-methylamphetamine: a summary
Risk Assessment Report of a new psychoactive substance: 4-methylamphetamine
Annex 1: Technical report on 4-methylamphetamine
Annex 2: Computational analysis on the pharmacology of 4-methylamphetamine
Council Decision 2013/129/EU on subjecting 4-methylamphetamine to control measures
Abbreviations
Participants of the risk assessment meeting
Foreword
Introduction
EMCDDA actions on monitoring and responding to new drugs
EMCDDA-Europol Joint Report on 4-methylamphetamine: a summary
Risk Assessment Report of a new psychoactive substance: 4-methylamphetamine
Annex 1: Technical report on 4-methylamphetamine
Annex 2: Computational analysis on the pharmacology of 4-methylamphetamine
Council Decision 2013/129/EU on subjecting 4-methylamphetamine to control measures
Abbreviations
Participants of the risk assessment meeting
Résumé :
This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug in the European Union led to an assessment of the health and social risks posed by the substance, and, consequently, its control across the EU Member States.
Affiliation :
Lisbon, Portugal